• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

垂体卒中:单中心功能性和非功能性垂体腺瘤 93 例综合分析。

Pituitary apoplexy: a comprehensive analysis of 93 cases across functioning and non-functioning pituitary adenomas from a single-center.

机构信息

Department of Endocrinology, Seth G.S Medical College & KEM Hospital, Mumbai, 400012, Maharashtra, India.

Department of Endocrinology, Vydehi Institute of Medical Sciences and Research Centre, Bangalore, Karnataka, India.

出版信息

Pituitary. 2024 Oct;27(5):705-713. doi: 10.1007/s11102-024-01453-5. Epub 2024 Sep 13.

DOI:10.1007/s11102-024-01453-5
PMID:39269545
Abstract

INTRODUCTION

Pituitary apoplexy (PA) is a rare clinical syndrome due to acute/subacute pituitary hemorrhage and/or infarction; data on PA in functioning pituitary adenoma (FPA) is scarce.

METHODS

A retrospective record-review of details of PA in non-functioning (NFPA) and FPA managed at tertiary endocrine center.

RESULTS

93 patients [56 males; 33.3% FPA: 5 acromegaly, 14 prolactinoma, and 12 Cushing's Disease (CD)] diagnosed with PA were included. Median age was 40 years, with younger age of presentation in FPA. Type A (acute) [49.5%] and headache (78.5%) were the commonest presentations, with PA being the initial manifestation in 98.4% of NFPA. Median (range) Pituitary Apoplexy Score (PAS) was 2 (0-8). Median tumor diameter was 2.5 cm, with larger tumors in FPA (3.2 cm vs. 2.3 cm). 29 (46.7%) NFPA-PA and 14 (45.2%) FPA-PA patients [71% prolactinoma, 33% in CD, and none in acromegaly] were conservatively managed. In the NFPA cohort, those managed surgically had significantly higher PAS (4 vs. 1) and larger tumor size (2.6 vs. 1.8 cm); however, both arms had comparable recovery of neuro-visual, radiological, and hormonal outcomes. In FPA cohort, CD and acromegaly required definitive treatment, whereas prolactinomas were effectively managed (clinical and biochemical recovery) with oral cabergoline and glucocorticoids. Matching PAS cohorts (to overcome allocation bias for management approach) in macroadenomas (excluding prolactinoma) showed comparable neuro-deficit and hormonal recovery between surgical and conservative approaches.

CONCLUSION

PA in FPA has distinct features and management issues. Carefully selected patients (PAS guided) in NFPA with PA for conservative management have comparable outcomes to surgery.

摘要

简介

垂体卒中是一种由于急性/亚急性垂体出血和/或梗死引起的罕见临床综合征;关于功能性垂体腺瘤(FPA)中垂体卒中的数据很少。

方法

回顾性记录和审查在三级内分泌中心管理的无功能性(NFPA)和 FPA 中垂体卒中的详细信息。

结果

共纳入 93 例患者[56 例男性;33.3%的 FPA:5 例肢端肥大症、14 例泌乳素瘤和 12 例库欣病(CD)]诊断为垂体卒中。中位年龄为 40 岁,FPA 的发病年龄较小。A型(急性)[49.5%]和头痛(78.5%)是最常见的表现,98.4%的 NFPA 患者以垂体卒中为首发表现。中位(范围)垂体卒中评分(PAS)为 2(0-8)。肿瘤直径中位数为 2.5cm,FPA 肿瘤较大(3.2cm 比 2.3cm)。29 例(46.7%)NFPA-PA 和 14 例(45.2%)FPA-PA 患者[71%为泌乳素瘤,33%为 CD,无一例为肢端肥大症]接受保守治疗。在 NFPA 队列中,手术治疗的患者 PAS 显著更高(4 分比 1 分),肿瘤体积更大(2.6cm 比 1.8cm);然而,两臂的神经视觉、影像学和激素恢复结果相当。在 FPA 队列中,CD 和肢端肥大症需要明确的治疗,而催乳素瘤通过口服卡麦角林和糖皮质激素可有效治疗(临床和生化恢复)。在排除泌乳素瘤的大腺瘤中,匹配 PAS 队列(克服治疗方法的分配偏倚),手术和保守治疗之间的神经缺损和激素恢复情况相当。

结论

FPA 中的垂体卒中具有独特的特征和管理问题。对 NFPA 中 PAS 指导下选择的具有 PA 的患者进行保守治疗,其结果与手术相当。

相似文献

1
Pituitary apoplexy: a comprehensive analysis of 93 cases across functioning and non-functioning pituitary adenomas from a single-center.垂体卒中:单中心功能性和非功能性垂体腺瘤 93 例综合分析。
Pituitary. 2024 Oct;27(5):705-713. doi: 10.1007/s11102-024-01453-5. Epub 2024 Sep 13.
2
Pituitary apoplexy in cushing's disease: a single center study and systematic literature review.库欣病垂体卒中:单中心研究和系统文献回顾。
Pituitary. 2024 Aug;27(4):335-344. doi: 10.1007/s11102-024-01411-1. Epub 2024 Jun 8.
3
The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011.2001-2011 年期间瑞典西部垂体腺瘤的发病率。
Eur J Endocrinol. 2014 Oct;171(4):519-26. doi: 10.1530/EJE-14-0144. Epub 2014 Aug 1.
4
A comparative study of functioning and non-functioning pituitary adenomas.垂体腺瘤的功能性与非功能性的对比研究。
Medicine (Baltimore). 2021 Apr 9;100(14):e25306. doi: 10.1097/MD.0000000000025306.
5
Apoplexy in pituitary macroadenoma: eight patients presenting in 12 months.垂体大腺瘤卒中:12个月内8例患者发病。
Medicine (Baltimore). 2005 May;84(3):188-196. doi: 10.1097/01.md.0000164205.77287.9e.
6
Spontaneous remission of acromegaly and Cushing's disease following pituitary apoplexy: Two case reports.垂体卒中后肢端肥大症和库欣病的自发缓解:两例报告
Neth J Med. 2015 Jun;73(5):242-6.
7
Management and outcomes of pituitary apoplexy.垂体卒中的管理与预后
J Neurosurg. 2015 Jun;122(6):1450-7. doi: 10.3171/2014.10.JNS141204. Epub 2015 Apr 10.
8
Digital analysis of hormonal immunostaining in pituitary adenomas classified according to WHO 2017 criteria and correlation with preoperative laboratory findings.根据世界卫生组织 2017 年标准分类的垂体腺瘤中激素免疫染色的数字分析及其与术前实验室检查结果的相关性。
Neurosurg Focus. 2020 Jun;48(6):E12. doi: 10.3171/2020.3.FOCUS2039.
9
Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas.功能性垂体腺瘤基线 T2 加权信号强度的临床病理意义。
Pituitary. 2018 Aug;21(4):347-354. doi: 10.1007/s11102-018-0877-3.
10
Clinical features and analysis in 1385 Chinese patients with pituitary adenomas.1385例中国垂体腺瘤患者的临床特征及分析
J Neurosurg Sci. 2013 Sep;57(3):267-75.

引用本文的文献

1
Pituitary Apoplexy in a Non-Functioning PitNET After Cabergoline Use: Case Report and Review of the Literature.使用卡麦角林后无功能垂体神经内分泌肿瘤发生垂体卒中:病例报告及文献复习
J Clin Med. 2025 Jul 17;14(14):5089. doi: 10.3390/jcm14145089.

本文引用的文献

1
Acromegaly complicated with fulminant pituitary apoplexy: clinical characteristic analysis and review of literature.肢端肥大症并发暴发性垂体卒中:临床特征分析及文献复习。
Endocrine. 2023 Jul;81(1):160-167. doi: 10.1007/s12020-023-03379-7. Epub 2023 May 17.
2
Differences in clinical, hormonal, and radiological presentation and in surgical outcomes in patients presenting with and without pituitary apoplexy. A multicenter study of 245 cases.有垂体卒中与无垂体卒中患者的临床、激素和影像学表现及手术结局的差异。一项 245 例患者的多中心研究。
Pituitary. 2023 Apr;26(2):250-258. doi: 10.1007/s11102-023-01315-6. Epub 2023 Apr 27.
3
Revisiting Pituitary Apoplexy.
垂体卒中再探讨。
J Endocr Soc. 2022 Jul 26;6(9):bvac113. doi: 10.1210/jendso/bvac113. eCollection 2022 Sep 1.
4
Towards a pituitary apoplexy classification based on clinical presentation and patient journey.基于临床表现和患者病程的垂体卒中分类方法。
Endocrine. 2022 Apr;76(1):132-141. doi: 10.1007/s12020-022-02983-3. Epub 2022 Jan 24.
5
Giant Prolactinoma Presenting With Facial Nerve Palsy and Hemiparesis.以面神经麻痹和偏瘫为表现的巨大泌乳素瘤
J Endocr Soc. 2021 Apr 14;5(9):bvab069. doi: 10.1210/jendso/bvab069. eCollection 2021 Sep 1.
6
COVID-19 and the pituitary.COVID-19 与垂体。
Pituitary. 2021 Jun;24(3):465-481. doi: 10.1007/s11102-021-01148-1. Epub 2021 May 3.
7
Radiological and clinical outcomes of pituitary apoplexy: comparison of conservative management versus early surgical intervention.垂体卒中的影像学和临床结局:保守治疗与早期手术干预的比较
J Neurosurg. 2021 Apr 30;135(5):1310-1318. doi: 10.3171/2020.9.JNS202899. Print 2021 Nov 1.
8
A comparative study of functioning and non-functioning pituitary adenomas.垂体腺瘤的功能性与非功能性的对比研究。
Medicine (Baltimore). 2021 Apr 9;100(14):e25306. doi: 10.1097/MD.0000000000025306.
9
A key role for conservative treatment in the management of pituitary apoplexy.保守治疗在垂体卒中治疗中的重要作用。
Endocrine. 2021 Jan;71(1):168-177. doi: 10.1007/s12020-020-02499-8. Epub 2020 Sep 21.
10
Visual and Endocrine Recovery Following Conservative and Surgical Treatment of Pituitary Apoplexy: A Meta-Analysis.保守治疗与手术治疗垂体卒中后视觉和内分泌功能的恢复:一项荟萃分析。
World Neurosurg. 2019 Dec;132:33-40. doi: 10.1016/j.wneu.2019.08.115. Epub 2019 Aug 27.